Michael Dale, President and CEO of ATS Medical commented, "Each year we look forward to the EACTS as one of the premier events within the cardiac surgeon community that we serve. This year is particularly exciting. After more than five years of investment and partnerships towards advancing the standard of cardiac surgery, the number of new and genuinely innovative product offerings from ATS in both our heart valve therapies and surgical ablation of cardiac arrhythmias businesses have never been greater. With new clinical updates on our novel Enable sutureless valve, our Forcefield technology, and our Open Pivot mechanical heart valve, we believe that ATS Medical will be of keen interest to many attendees during this year's EACTS meeting."
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 160,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.
Safe Harbor
This Press Release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the Company
and its management. Actual results could differ materially from those
projected in the forward-looking statements as a result of a
'/>"/>
| SOURCE ATS Medical, Inc. Copyright©2008 PR Newswire. All rights reserved |